To develop an oxaborole for Chagas disease
current phase of drug development
updated 1 Jun 2021
There is an urgent need for new treatments that can be used for both the acute and chronic stages of Chagas disease and that are safer and more effective than current treatment regimens, which use benznidazole and nifurtimox.
The oxaborole DNDI-6148 has emerged as a promising lead candidate for visceral leishmaniasis and cutaneous leishmaniasis; it has also shown efficacy against Chagas disease in an in vivo model and its potential for further development is being assessed.
Get our latest news, personal stories, research articles, and job opportunities.